The
US generics market was estimated at US$18.1 billion
in 2004; the leading European generics markets together
totalled between US$10 and US$11 billion for the
same period. This new report asks why there is such
a difference in value. Contrasts in regulatory systems,
legislative background and market characteristics
increase the difficulties for companies from one
area who are trying to enter another market.
US
and European Prescription Generic Markets reviews
these divergent characteristics and also looks at
those areas where the two sides are moving closer
together. One major finding that emerges from this
analysis is the surprising absence of the majority
of US domestic generic companies from overseas markets.
The report contrasts this with the increasing presence
of foreign generic companies in the US, looks at
where these new competitors have come from and assesses
how much of a threat they represent to the major
US companies.
US
and European Prescription Generic
Markets
provides an in-depth examination of:
-
Successful
generic growth strategies and how they vary
-
Defensive tactics of the multinationals
-
Generic industry growth prospects and possible
threats
-
A
history of the generic markets
-
The legislative and regulatory background
-
How
differences between the US and European markets
have developed
-
Who are the major players and how they rose to
the top
|
